11 recruiting, 6 unknown, 4 completed, 2 not yet recruiting. 25 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Recruiting 11, Unknown 6, Completed 4, Not yet recruiting 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Chemoradiotherapy: new trials by email Literature Review of Chemoradiotherapy trials Research Report on Chemoradiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer SHR-1701 combined with platinum-doublet chemotherapy induction therapy, SHR-1701 consolidation therapy, Platinum-doublet chemotherapy - NSCLC Stage III, SHR-1701 | Phase 2 | Not yet recruiting | Fudan University | 84 | 2026-07-01 | 2026-06-02 |
| Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC Ensartinib 225mg, Placebo Ensartinib 225mg - NSCLC Stage III, Ensartinib | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-12-01 | 2025-11-19 |
| A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy QL1706 (bispecific antibody targeting PD-1 and CLTA-4) - Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy | Phase 2 | Recruiting | Shanghai Chest Hospital | 28 | 2025-10-23 | 2026-06-11 |
| SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC PD-1 inhibitor based immunotherapy - Rectal Cancer, Rectal Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 104 | 2025-09-05 | 2025-09-30 |
| Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents - Myelosuppression, Thoracic Neoplasms | Phase 2 | Recruiting | Affiliated Hospital of Nantong University | 30 | 2025-08-01 | 2025-12-11 |
| Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant immunochemotherapy, Surufatinib Administration, Concurrent Chemotherapy - Toripalimab, Surufatinib | Phase 2 | Recruiting | Sun Yat-sen University | 69 | 2025-07-20 | 2025-11-17 |
| Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. Radiation Therapy, Chemoradiotherapy, Consolidation Chemotherapy - Rectal Cancer, Total Neoadjuvant Treatment | Phase 2 / Phase 3 | Recruiting | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | 400 | 2025-01-06 | 2026-05-11 |
| Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer Chemotherapy, Immunotherapy, Angio-immuno kinase inhibitor - Toripalimab, Surufatinib | Phase 2 | Recruiting | Sun Yat-sen University | 47 | 2024-11-30 | 2026-03-03 |
| Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma Sintilimab - Esophageal Cancer, Chemoradiotherapy | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 191 | 2024-06-01 | 2024-07-16 |
| Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy sodium glycididazole - Chemoradiotherapy | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2024-05-29 | 2024-10-31 |
| Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery - Esophageal Cancer, Immunotherapy | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2024-05-01 | 2025-05-30 |
| Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma Nimotuzumab with chemoradiotherapy - Esophageal Cancer, Nimotuzumab | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 53 | 2023-03-01 | 2024-05-13 |
| Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients Nimotuzumab with chemoradiotherapy - Esophageal Cancer, Nimotuzumab | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 55 | 2023-03-01 | 2024-05-28 |
| Evaluation the Effects of Herbal Gargle for Chemoradiotherapy-induced Oral Mucositis of Head & Neck Cancer, a Pilot Study. Herbal gargle, Normal saline - Head and Neck Neoplasms, Chemoradiotherapy | Phase 2 | Unknown | Chang Gung Memorial Hospital | 80 | 2022-04-15 | 2022-04-22 |
| PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer Camrelizumab plus Concurrent chemoradiotherapy - Cervical Carcinoma, Chemoradiotherapy | Phase 2 | Unknown | Lei Li | 92 | 2022-03-27 | 2022-04-13 |
| Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab - Stomach Neoplasms, Esophagogastric Junction Disorder | Phase 2 | Terminated | Fudan University | 6 | 2021-09-28 | 2025-06-18 |
| Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer PD-1 antibody, Chemoradiation, Albumin-Bound Paclitaxel - Esophagus Cancer, Chemoradiotherapy | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 35 | 2020-10-01 | 2025-05-30 |
| Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) Paclitaxel, Carboplatin, Radiotherapy - Esophagus Cancer, Esophageal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Fudan University | 70 | 2020-05-30 | 2023-08-03 |
| A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer Radiotherapy, Nimotuzumab, S-1 - Esophageal Cancer, Chemoradiotherapy | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 55 | 2019-11-14 | 2024-05-16 |
| Chemoradiotherapy in Unresectable Esophageal Cancer Radiotherapy, Albumin-Bound Paclitaxel, Cisplatin - Esophageal Cancer, Chemoradiotherapy | Phase 1 / Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 105 | 2019-10-01 | 2024-12-13 |
Showing 20 of 25. Sign in to see all of them.
Esophageal Neoplasms (8) · Rectal Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Squamous Cell Carcinoma (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Fatigue (1) · Febrile Neutropenia (1) · Head and Neck Neoplasms (1) · Low Anterior Resection Syndrome (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Neutropenia (1) · Postoperative Complications (1)
Neoplasms (22) · Neoplasms by Site (22) · Digestive System Diseases (14) · Digestive System Neoplasms (14) · Gastrointestinal Diseases (14) · Gastrointestinal Neoplasms (14) · Head and Neck Neoplasms (10) · Esophageal Diseases (9) · Bronchial Neoplasms (4) · Carcinoma (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Lung Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4)
Chemoradiotherapy (7) · Radiotherapy (7) · nimotuzumab (3) · Albumin-Bound Paclitaxel (2) · Capecitabine (2) · Cisplatin (2) · Oxaliplatin (2) · S 1 (combination) (2) · Surgical Procedures, Operative (2) · sintilimab (2) · toripalimab (2) · 130-nm albumin-bound paclitaxel (1) · Carboplatin (1) · Consolidation Chemotherapy (1) · Drug Therapy (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (7) · Fudan University (3) · Sun Yat-sen University (2) · Affiliated Hospital of Nantong University (1) · Chang Gung Memorial Hospital (1) · Chinese Academy of Medical Sciences (1) · Kangbuk Samsung Hospital (1) · Lei Li (1) · National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos (1) · Peking University (1) · Ruijin Hospital (1) · Shanghai Chest Hospital (1) · Shanghai Jiao Tong University School of Medicine (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Sichuan Cancer Hospital and Research Institute (1)
China (19) · Lithuania (1) · South Korea (1) · Taiwan (1)
Audrius Dulskas, PhD (1) · Dong-Hoe Koo (1) · Hui Liu (1) · Hui Liu, Professor (1) · Kuaile Zhao (1) · Lei Deng, MD (1) · Lei Li, M.D. (1) · Ren Zhao, MD, PhD (1) · Weiguo Cao, MD (1) · Xin Wang (1) · Xin Wang, MD (1) · Yongheng Li, MD (1) · Yongling Ji (1) · Ziyu Li, MD (1)